Electronic patient-reported monitoring of symptoms during follow-up of ovarian cancer patients: a feasibility study

BMC Cancer. 2022 Jul 2;22(1):726. doi: 10.1186/s12885-022-09817-5.

Abstract

Background: Ovarian cancer patients require monitoring for relapse. Innovative follow-up methods are increasingly being explored. An electronic patient-reported outcome (ePRO) follow-up pathway was developed for women treated for ovarian cancer. This feasibility study explored patient acceptability and compliance.

Methods: A single-arm non-blinded prospective feasibility study was undertaken at two hospitals. Participants were women who had completed treatment for ovarian cancer whose clinician was happy for them to be monitored remotely. Automated 3-monthly reminders were sent to participants to complete an ePRO questionnaire and obtain blood tests. Participants were reviewed over the phone by their clinical nurse specialist instead of attending clinic-based follow-up. The primary outcome was compliance (expected ePRO completions/blood tests) across the 12-month study period. Secondary outcomes were recruitment, attrition, resource use, symptom severity/alerts and patient acceptability.

Results: Twenty-four women consented (50% consent rate), and 13 remained on study at 12 months. Seven women relapsed, 3 chose to withdraw, and 1 withdrew for other clinical reasons. ePRO compliance was high and consistent at 75-82%, although the two hospitals differed. Adherence to the clinical protocol was evident for blood tests and contacts with staff (fewer visits, more phonecalls compared to an earlier audit). End-of-study feedback indicated high patient satisfaction.

Conclusions: Remote ePRO follow-up for ovarian cancer is feasible and acceptable to patients who are able and willing to participate. However, the low recruitment rate (ineligible + declined) indicate it is not suitable/acceptable to all patients immediately post-treatment. Further large-scale research and implementation work is required, especially in a post-COVID era.

Trial registration: ClinicalTrials.gov ID: NCT02847715 (first registered 19/05/2016).

Keywords: Acceptability; Compliance; Electronic patient-reported outcomes; Feasibility study; Follow-up; Ovarian cancer.

Publication types

  • Clinical Study

MeSH terms

  • Carcinoma, Ovarian Epithelial
  • Electronics
  • Feasibility Studies
  • Female
  • Follow-Up Studies
  • Humans
  • Neoplasm Recurrence, Local
  • Ovarian Neoplasms* / diagnosis
  • Ovarian Neoplasms* / therapy
  • Patient Reported Outcome Measures
  • Prospective Studies

Associated data

  • ClinicalTrials.gov/NCT02847715